(Total Views: 383)
Posted On: 09/29/2021 5:19:46 PM
Post# of 148892
forego NASH interim?
i sincerely hope they did NOT decide to forgo interim analysis...that mistake cost us CD10/12 and put us in the position we are in today. had we paid the statistical price back then we would have EUA buy now. we also need the interim analysis for the good news and stock price bump to ward off 13D NOW...never too much ammunition to win a war.
Quote:
Quote: These Nash results were intern results correct? So does this mean enrollment of the rest of the trial. I wonder if they have the data for current results and know they have to complete enrollment to hit their endpoint.
They have full enrollment for the current NASH trial. It's possible they decided to forego the interim analysis on the first 50 patients saving the time and money and just waiting until the 60 finish up. For enrolling NASH this year they're talking about a phase 3 trial but that will be dependent on what the FDA will want for the number of patients. Results from the phase 2 might indicate a fairly small number needed to hit the primary endpoint the FDA will probably require more.
Speed of enrollment is also going to be dependent on money and the number of trial sites. If share price is sufficiently high they'll probably sell enough shares to increase trial sites. If not they may wait until revenue and ramp them up fast.
Read More: https://investorshangout.com/post/newpost/605...z77tIabg9t
i sincerely hope they did NOT decide to forgo interim analysis...that mistake cost us CD10/12 and put us in the position we are in today. had we paid the statistical price back then we would have EUA buy now. we also need the interim analysis for the good news and stock price bump to ward off 13D NOW...never too much ammunition to win a war.
(3)
(0)Scroll down for more posts ▼
